SEC Company Response from Edesa Biotech, Inc. (EDSA) (CIK 0001540159) (EDSA) — Mar 4, 2020
Edesa Biotech, Inc. (EDSA) (CIK 0001540159)
Date: March 4, 2020 · CIK: 0001540159 · Accession: 0001654954-20-002234
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236608
Letter
United States Securities and Exchange Commission Attention: Ada D. Sarmento Division of Corporation Finance Washington, D.C. 20549 RE: Edesa Biotech, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) File Number 333-236608
Dear Ms. Sarmento:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effectiveness of the Registration Statement so that such Registration Statement will become effective as of 5:00 P.M. on Friday, March 6, 2020, or as soon thereafter as practicable.
Very truly yours,
EDESA BIOTECH, INC.
Show Raw Text
CORRESP 1 filename1.htm Blueprint Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6 March 4, 2020 United States Securities and Exchange Commission Attention: Ada D. Sarmento Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Edesa Biotech, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) File Number 333-236608 Dear Ms. Sarmento: The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effectiveness of the Registration Statement so that such Registration Statement will become effective as of 5:00 P.M. on Friday, March 6, 2020, or as soon thereafter as practicable. Very truly yours, EDESA BIOTECH, INC. By: /s/ Kathi Niffenegger Name: Kathi Niffenegger Title: Chief Financial Officer